GlaxoSmithKline And Theravance Announce Start Of Large Phase 2B ICS And LABA Studies For Asthma In The Horizon Program
Jan 4th 2008Drug InformationClinical Trials
GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (Nasdaq: THRX) announced the start of large Phase 2b asthma dose-optimization studies with both the lead inhaled corticosteroid (ICS) GW685698 (’698) and the lead long-acting beta agonist (LABA) GW642444 (’444) assets in the ‘Horizon’ program to develop a next-generation combination product.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
